ArticleBMC infectious diseases2026
Landscape of resistance to ceftolozane/tazobactam and ceftazidime/avibactam in strains of Pseudomonas aeruginosa: a genomic approach in strains without selection pressure in a tertiary-care paediatric hospital in Mexico.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundCarbapenems are reserved as a last-line therapy for infections caused by Pseudomonas aeruginosa. However, the resistance to these antibiotics exceeds 24.2%, and in paediatric patients, infections caused by carbapenem-resistant P. aeruginosa (CR-PA) have a mortality between 25 and 38.2%. Therefore, antimicrobial agents such as ceftazidime/avibactam (CZA) and ceftolozane/tazobactam (CT) have been developed. This study aimed to characterize CT- and CZA-non-susceptible P. aeruginosa isolates from paediatric patients in a hospital where these therapeutic agents are not yet available.
methodsFifty-nine nonduplicate carbapenem-resistant and non-carbapenemase-producing isolates of P. aeruginosa from infected paediatric patients were analysed. Susceptibility to CT and CZA was determined with the disc diffusion method, epsilometry, and semiautomated microdilution. Sixteen isolates were selected for whole-genome sequencing. Bioinformatic analyses were used to identify acquired resistance genes and point mutations, and to determine the sequence type (ST) and clonal relationships in both local and international contexts.
resultsA total of 64.5% of the isolates were susceptible to CT and CZA. Among the resistant isolates, we identified serogroups O5, O4, O11, and O3, as well as ST348, ST389, and the high-risk clone ST309. Genes related to resistance to beta-lactams, fluoroquinolones (FQs), aminoglycosides, and other antimicrobial agents were identified. Mutations were found in the ampC gene (T105A) and in the regulatory genes ampR, mexR and nalC. All isolates carried the virulence factors exoA, phzA, algD, lecA, and lasA; 61.5% carried lasB; and 46.1%, pilA. Two major clusters were identified, one composed of ST348 and the other of ST389, which clustered with strains from China and Spain, respectively.
conclusionThis study reports the emergence of CT and CZA resistance in P. aeruginosa isolates from a paediatric hospital in Mexico prior to their clinical use. Genomic analyses showed alignment with global strains and revealed clonal relationships in ST348 and ST389, as well as the presence of the high-risk clone ST309. No known resistance-associated mutations were identified, suggesting pre-existing cross-resistance. Future studies integrating WGS with functional and transcriptomic approaches will be required to elucidate additional mechanisms. CLINICAL TRIAL: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.